| scholarly article | Q13442814 |
| P50 | author | Pascal Lutumba | Q28817154 |
| Marleen Boelaert | Q28817180 | ||
| Raquel Inocêncio da Luz | Q41844171 | ||
| P2093 | author name string | David Hendrickx | |
| Alain Mpanya | |||
| Crispin Lumbala | |||
| Sylvain Baloji | |||
| P2860 | cites work | Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial | Q28250035 |
| Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda | Q28469079 | ||
| Should I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of Congo | Q28478935 | ||
| Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis | Q56504613 | ||
| Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee | Q58842952 | ||
| Human African Trypanosomiasis in the Democratic Republic of the Congo: A Looming Emergency? | Q29056943 | ||
| Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis | Q33989166 | ||
| Treatment outcomes for human African Trypanosomiasis in the Democratic Republic of the Congo: analysis of routine program data from the world's largest sleeping sickness control program | Q34342721 | ||
| Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study | Q34589130 | ||
| NTDs in the heart of darkness: the Democratic Republic of Congo's unknown burden of neglected tropical diseases | Q34927340 | ||
| Barriers to treatment access for Chagas disease in Mexico | Q35023674 | ||
| Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. | Q36740553 | ||
| High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo | Q37009244 | ||
| Human African trypanosomiasis in a rural community, Democratic Republic of Congo | Q37302722 | ||
| Chemotherapy against human African trypanosomiasis: Is there a road to success? | Q37801690 | ||
| Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis | Q37811110 | ||
| Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis | Q37981773 | ||
| Rapid diagnostic tests for neurological infections in central Africa | Q38102421 | ||
| Socio-entomologic survey in human trypanosomiasis focus of Yamba (Peoples Republic of Congo) | Q38512410 | ||
| Clinical aspects of 2541 patients with second stage human African trypanosomiasis | Q38912264 | ||
| Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo | Q39401306 | ||
| The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo | Q39401311 | ||
| Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal. | Q39510687 | ||
| Control and surveillance of human African trypanosomiasis | Q39603203 | ||
| The treatment of human African trypanosomiasis | Q40721903 | ||
| The use of oral corticosteroids in the treatment of human African trypanosomiasis: a retrospective survey in Nioki, Zaire | Q46795231 | ||
| Hot-cold food and medical theories: overview and introduction | Q47402313 | ||
| Clinical and pathological aspects of human African trypanosomiasis (T. b. gambiense) with particular reference to reactive arsenical encephalopathy | Q48390417 | ||
| Problems for the chemotherapy of human African trypanosomiasis. | Q48625775 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Democratic Republic of the Congo | Q974 |
| African trypanosomiasis | Q203133 | ||
| P304 | page(s) | e0003686 | |
| P577 | publication date | 2015-04-09 | |
| P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
| P1476 | title | From health advice to taboo: community perspectives on the treatment of sleeping sickness in the Democratic Republic of Congo, a qualitative study | |
| P478 | volume | 9 |
| Q52681953 | "Kala-Azar is a Dishonest Disease": Community Perspectives on Access Barriers to Visceral Leishmaniasis (Kala-Azar) Diagnosis and Care in Southern Gadarif, Sudan. |
| Q58842233 | Ethical Considerations for Global Health Decision-Making: Justice-Enhanced Cost-Effectiveness Analysis of New Technologies for |
| Q92616533 | Gambian human African trypanosomiasis in North West Uganda. Are we on course for the 2020 target? |
| Q57061698 | Knowledge, attitudes and practices about human African trypanosomiasis and their implications in designing intervention strategies for Yei county, South Sudan |
| Q92264389 | New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice |
| Q28555206 | Predicting the Impact of Intervention Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic Republic of Congo |
| Q36202328 | Quantitative evaluation of the strategy to eliminate human African trypanosomiasis in the Democratic Republic of Congo. |
| Q36037787 | We Remember… Elders' Memories and Perceptions of Sleeping Sickness Control Interventions in West Nile, Uganda |
Search more.